French biotechnology company Transgene (Euronext Paris:TNG) and ProBioGen, a contract development and manufacturing organisation (CDMO) in biologics, vaccines and viral vectors, announced on Tuesday that they have joined forces to accelerate the development of personalised cancer vaccines.

Through a licence agreement, ProBioGen's high-yielding AGE1.CR.pIX cell line will be integrated into Transgene's myvac platform for large-scale production.

This collaboration leverages ProBioGen's established bioprocessing technology with Transgene's expertise in individualised cancer immunotherapy. The partnership aims to streamline manufacturing processes, ensuring consistent and cost-effective production of patient-specific cancer treatments.